Clinical Trial Update: Relative Bioavailability and Activity of Different Formulations of Insulin Glargine and Lixisenatide in Patients With Diabetes Mellitus Type 1 [Phase 1]

View source ↗

Summary

A Phase 1 study by Sanofi assesses the relative bioavailability and activity of different formulations of insulin glargine and lixisenatide in adults with Type …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Insulin Glargine (insulin glargine)
• Lixisenatide (lixisenatide)

Snippet

Sponsor: Sanofi | Conditions: Type 1 Diabetes Mellitus | Phase 1 | Status: COMPLETED